Mitrix Bio CEO on how targeting increased longevity for astronauts could also pay dividends for those back on planet Earth.

Mitrix Bio recently announced the creation of a new subsidiary, Biotech Explorers, that is aiming to achieve a 130 year lifespan in humans. Initially focused on astronauts, and bringing benefits for those suffering from early-aging diseases, the trials will transplant bioreactor-grown mitochondria into volunteers to increase the number of functional mitochondria.

In addition to extended lifespan, Biotech Explorers also hopes to demonstrate rapid wound healing, enhanced radiation and infection resistance and muscle generation. Initially intended to make space travel less dangerous and debilitating, the implications for earthbound therapies are obvious. We sat down with Mitrix Bio CEO Tom Benson to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Mitrix Bio: https://www.mitrix.bio/
More about Biotech Explorers: https://www.explorers.bio/